The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 36, No. 10, pp. 1554-1557. DOI 10.1345/aph.1C074
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, C.
Right arrow Articles by Fugate, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, C.
Right arrow Articles by Fugate, S.


Research Articles

Levofloxacin and warfarin interaction

CB Jones and SE Fugate

OBJECTIVE: To report 4 cases of hypoprothrombotic response resulting from addition of levofloxacin therapy to chronic warfarin therapy and to review related literature to support or refute a warfarin-levofloxacin interaction. CASE SUMMARY: Four patients, 34-81 years old, were prescribed levofloxacin concomitantly with stable warfarin therapy. Three patients had a target international normalized ratio (INR) range of 2.0-3.0 and experienced an increase in INR to 3.5, 8.12, and 11.5 on days 11, 5, and 4 of a 10-day course of levofloxacin, respectively. The fourth patient experienced minor bleeding, with a slightly elevated INR on the second day of levofloxacin therapy that required up to a 19% warfarin dose reduction during levofloxacin treatment. DISCUSSION: An initial premarketing clinical trial concluded that levofloxacin had no effect on warfarin's pharmacokinetics and pharmacodynamic response. Two case reports have since documented an increase in INR in patients taking long-term warfarin on completion of levofloxacin therapy. Our case reports provide further evidence of a significant increase in INR observed during concomitant levofloxacin therapy. The proposed mechanism of this interaction is displacement of warfarin from protein binding sites, reduction in gut flora producing vitamin K, and decreased warfarin metabolism. CONCLUSIONS: Prolonged prothrombin response in patients undergoing chronic warfarin therapy has been well documented with many antibiotics, including fluoroquinolones. Recognition of newer antibiotics' effects on warfarin therapy is important to guide safe use and monitoring of anticoagulation therapy. Our case studies demonstrate significant elevations in INR values during and up to 1 day after levofloxacin therapy in patients undergoing stable warfarin therapy.


This article has been cited by other articles:


Home page
The Annals of PharmacotherapyHome page
D. N Carroll and D. G Carroll
Interactions Between Warfarin and Three Commonly Prescribed Fluoroquinolones
Ann. Pharmacother., May 1, 2008; 42(5): 680 - 685.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
D. J. Greenblatt and L. L. von Moltke
Interaction of Warfarin With Drugs, Natural Substances, and Foods
J. Clin. Pharmacol., February 1, 2005; 45(2): 127 - 132.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
D. H. Elbe and S. W Chang
Moxifloxacin-Warfarin Interaction: A Series of Five Case Reports
Ann. Pharmacother., February 1, 2005; 39(2): 361 - 364.
[Abstract] [Full Text] [PDF]


Home page
CMAJHome page
K. Airey and E. Koller
Acute hepatitis associated with levofloxacin in a patient with renal insufficiency
Can. Med. Assoc. J., October 14, 2003; 169(8): 755 - 755.
[Full Text]




homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.